Fundamentals-based quality & risk · not a recommendation
Raw blend 75 capped to 55 by a red flag.
Raw blend 75 → capped to 55
Par Drugs & Chemicals Ltd scores 55/100 (Watch) on the Orion Score — strong business quality (76), weak growth (49), strong balance-sheet safety (93) and cheap valuation (82). A fundamentals-based quality & risk score, not a buy/sell recommendation.
Risk checks
Forensic accounting
Piotroski F = fundamental health (0–9, higher is better) · Altman Z = bankruptcy / distress risk · Beneish M = earnings-manipulation check
Technical / Momentum
Price Trend
52/100
Technical momentum companion — separate from the fundamentals-based Orion Score.
Unlock with Pro
Upgrade →Q4 FY2026
Revenue & Profit in ₹ Crores
| Quarter | Revenue | Net Profit | OPM | EPS |
|---|---|---|---|---|
| Q4 2026 | ₹19.61 | ₹0.85 | 2.6% | ₹0.69 |
| Q3 2026 | ₹29.34 | ₹4.8 | 17.5% | ₹3.90 |
| Q2 2026 | ₹28.66 | ₹4.13 | 17.9% | ₹3.36 |
| Q1 2026 | ₹26.05 | ₹3.33 | 10.2% | ₹2.70 |
| Q4 2025 | ₹22.33 | ₹1.65 | 6.8% | ₹1.34 |
Revenue & Profit in ₹ Crores (Yearly)
| Year | Revenue | Net Profit | EBITDA | OPM |
|---|---|---|---|---|
| FY 2026 | ₹103.66 | ₹13.11 | ₹21.13 | 13.0% |
| FY 2025 | ₹100.97 | ₹13.36 | ₹21.65 | 15.7% |
| FY 2024 | ₹95.11 | ₹14.5 | ₹22.95 | 21.2% |
| FY 2023 | ₹95.1 | ₹11.33 | ₹18.31 | 15.3% |
Top companies in the same sector by market cap
| Company | Mkt Cap | P/E | ROCE | ROE | D/E | OPM |
|---|---|---|---|---|---|---|
| PAR ★ | ₹111 Cr | 8.44 | 11.63% | 12.43% | — | 2.62% |
| SUNPHARMA | ₹4,27,609 Cr | 37.32 | 15.73% | 14.72% | 0.06x | 18.90% |
| MAXHEALTH | ₹95,110 Cr | 66.21 | 11.94% | 14.33% | 0.32x | 22.56% |
| AUROPHARMA | ₹90,029 Cr | 25.94 | 12.55% | 9.93% | 0.21x | 15.11% |
| ABBOTINDIA | ₹57,724 Cr | 36.63 | 36.14% | 34.46% | 0.04x | 27.01% |
| AJANTPHARM | ₹41,836 Cr | 39.55 | 27.99% | 25.39% | 0.06x | 51.40% |
All values in ₹ Crores
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total Assets | ₹119.39 | ₹101.61 | ₹88.87 | ₹78.69 |
| Equity | ₹98.97 | ₹85.63 | ₹71.24 | ₹59.88 |
| Total Debt | — | — | — | — |
| Cash | ₹27.58 | ₹36.65 | ₹22.24 | ₹16.21 |
| Net Debt | — | — | — | — |
| Working Capital | ₹38.29 | ₹47.18 | ₹35.45 | ₹28.71 |
Q3 FY2026
Quarter-over-Quarter Trend
| Quarter | Promoter | FII | DII | Public |
|---|---|---|---|---|
| Q3 FY2026 | 73.41% ↑ | 0% | 0% | 26.59% ↓ |
| Q2 FY2026 | 73.37% | 0% | 0% | 26.63% |
| Q1 FY2026 | 73.37% | 0% | 0% | 26.63% |
| Q4 FY2025 | 73.37% | 0% | 0% | 26.63% |
| Q3 FY2025 | 73.37% | 0% ↓ | 0% | 26.63% ↑ |
| Q2 FY2025 | 73.37% ↓ | 0.09% ↓ | 0% | 26.54% ↑ |
| Q1 FY2025 | 74.21% | 0.32% ↑ | 0% ↓ | 25.47% ↓ |
| Q4 FY2024 | 74.21% | 0.07% | 0.05% | 25.68% |
No recent corporate actions
Ask: "Is Par Drugs & Chemicals Ltd stock a good buy right now?" — Get RSI, MACD, ROCE + AI recommendation
Analyse with OrionGet free stock analysis, market insights, and investment ideas delivered to your inbox.
No spam. Unsubscribe anytime.
Par Drugs & Chemicals Ltd is listed on the NSE under the Healthcare sector, Pharmaceuticals industry. ISIN: INE04LG01015. Track live share price, technical analysis, RSI, MACD, PE ratio, and smart money holdings on VestAI — India's AI-powered stock analysis platform.